alles over ongeneeslijke ziektes

Hair and nails

Safety of low-dose oral minoxidil treatment for hair loss. A systematic review and pooled-analysis of individual patient data.

5 Repeated evidence

How much this weighs: several studies in people, combined — the strongest kind of evidence there is.
Type of study
meta-analysis or systematic review
Studied in
people
Participants
442
Published
2021 in Dermatologic therapy
Cited
17 times by other research
Who paid
Not declared. PubMed carries no conflict-of-interest statement for most articles; that is not the same as independent.
Source
PubMed 32757405 · doi 10.1111/dth.14106
The plain-language write-up of this study is still being written. Below is the abstract exactly as the researchers published it.
Abstract by the researchers — original text

low dose oral minoxidil (OM) is an increasingly used treatment for androgenetic alopecia and other types of hair loss. to analyze available data of patients treated with OM, focusing on safety and adverse effects. a search in PubMed and EMBASE was performed for studies reporting the treatment of alopecia with OM. Individual patient data available for pooled-analysis were sex, dose of OM, presence of hypertrichosis and lower limb edema. 14 studies including 442 patients were analyzed. OM was used at doses between 0.25 and 5 mg, for eight different types of alopecia. Hypertrichosis was observed in 24% of patients. All doses had an increased odds ratio of hypertrichosis, compared to 0.25 to 0.5 mg (P < .001). Pedal edema was observed in 2% and was also associated with higher doses of OM (P = .009). Postural hypotension and heart rate alterations occurred only in 1.1% and 1.3% of the patients, respectively. Efficacy of OM could not be analyzed due to heterogeneous studies. However, four studies using OM for androgenetic alopecia reported a clinical response in 70% to 100% of the patients. Low dose OM is a safe and well-tolerated treatment for hair loss, presenting a lower adverse effect rate than standard doses.